Stocktoria
TherapeuticsMD, Inc. TXMD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2001-01-31
TherapeuticsMD, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M |
| Gross profit | — | — | $1.3M | $68.6M | $1.2M |
| R&D expense | — | — | — | — | $7.1M |
| SG&A expense | — | $4.7M | $8.9M | — | — |
| Operating income | -$4.4M | -$6.1M | -$8.5M | $1.2M | -$79.6M |
| Interest expense | — | — | $300,000 | $200,000 | $32.9M |
| Income tax | — | -$31,000 | -$43,000 | — | — |
| Net income | -$569,000 | -$2.2M | -$10.3M | $112.0M | -$172.4M |
| EPS (diluted) | $-0.05 | $-0.19 | $-0.99 | $11.96 | $-21.66 |
| Operating cash flow | $2.5M | $1.2M | -$23.1M | $9.4M | -$142.7M |
| Free cash flow | — | — | — | — | -$142.7M |
| Cash & equivalents | — | $5.1M | $4.3M | — | — |
| Inventory | — | — | — | — | $7.6M |
| Total assets | $37.7M | $38.8M | $43.3M | $90.5M | $169.5M |
| Total liabilities | $10.8M | $11.5M | $14.0M | $55.3M | $263.1M |
| Shareholders' equity | $26.9M | $27.4M | $29.3M | $35.1M | -$93.6M |
Source: SEC EDGAR filings · CIK 0000025743 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.